S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

NCT03457337 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced NSCLC With EGFR Mutation

Interventions

DRUG: S-1 plus Gefitinib
DRUG: Gefitinib

Sponsor

Henan Cancer Hospital